Use

Mutations within the BCR-ABL1 kinase domain of patients with chronic myeloid leukemia or acute lymphoblastic leukemia with Philadelphia chromosome are the most commonly identified mechanism associated with resistance to kinase inhibitors. It has been reported that most patients with detectable BCR‑ABL1 kinase domain mutations are imatinib resistant or resistant to other kinase inhibitors. This assay includes analysis for T315I, the most commonly reported imatinib resistance mutation, which is also resistant to two second generation tyrosine kinase inhibitors, nilotinib and dasatinib. Failure to achieve cytogenetic response in the first 6 months of therapy in CML patients often reflects the presence of mutations or a high probability that mutations will subsequently be detected.